KEYNOTE-365 cohort c updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients with metastatic Castration-Resistant Prostate Cancer (mCRPC)

KEYNOTE-365 cohort c updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients with metastatic Castration-Resistant Prostate Cancer (mCRPC)

Bibliographic Details
Main Authors:	S. Feyerabend, W. Berry, P. Fong, J.M. Piulats, L. Appleman, H. Conter, N. Shore, G. Gravis, B. Laguerre, H. Gurney, M. Retz, E. Romano, L. Mourey, J. De Bono, A. Kam, U. Emmenegger, H. Wu, C. Schloss, C. Poehlein, E.Y. Yu
Format:	Article
Language:	English
Published:	Elsevier 2020-07-01
Series:	European Urology Open Science
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666168320331657

Similar Items

KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC)
by: G. Gravis, et al.
Published: (2020-07-01)

347 KEYNOTE-365 cohort C: pembrolizumab + enzalutamide in patients with abiraterone acetate–pretreated metastatic castration-resistant prostate cancer (mCRPC)—data after minimum of 22 months of follow-up
by: Urban Emmenegger, et al.
Published: (2021-11-01)

Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A updated results
by: J.M. Piulats, et al.
Published: (2020-07-01)

Pain outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving enzalutamide (ENZA) in a real-world setting: PREMISE
by: D. Mott, et al.
Published: (2020-07-01)

Withdrawal syndrome and PSA flare in the management of mCRPC with abiraterone
by: Po Hui Chiang
Published: (2015-12-01)

Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC
by: Florian Rosar, et al.
Published: (2022-03-01)

Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison
by: Pui S. Tan, et al.
Published: (2014-01-01)

Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison
by: Pui S. Tan, et al.
Published: (2014-03-01)

Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
by: Vincenza Conteduca, et al.
Published: (2022-04-01)

344 Phase 3 trial of pembrolizumab and enzalutamide versus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) (KEYNOTE-641)
by: Arnulf Stenzl, et al.
Published: (2020-11-01)

Breaking through resistance in mCRPC: Enzalutamide analogues as effective anticancer agents for enhanced male survival
by: Ritesh P. Bhole, et al.
Published: (2023-12-01)

345 Phase 3 study of combination pembrolizumab + olaparib therapy versus enzalutamide/abiraterone in metastatic castration-resistant prostate cancer (mCRPC) after progression on chemotherapy (KEYLYNK-010)
by: Lu Xu, et al.
Published: (2020-11-01)

Prostate-speciﬁc antigen response after Abiraterone treatment in mCRPC: PSA as a predictor of overall survival
by: Alexandre Mendonça Macedo, et al.
Published: (2023-02-01)

Management of elderly mCRPC patients
by: Seiichiro Ozono
Published: (2015-12-01)

Very Early PSA Response to Abiraterone in mCRPC Patients: a Novel Prognostic Factor Predicting Overall Survival
by: Gaetano eFacchini, et al.
Published: (2016-05-01)

Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives
by: H. Taghizadeh, et al.
Published: (2019-11-01)

Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate
by: Jiang-Yi Wang, et al.
Published: (2022-01-01)

341 Phase 1b/2 study of BXCL701, an oral activator of the systemic innate immunity pathway, combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC)
by: Lawrence Karsh, et al.
Published: (2020-11-01)

Clinical case long-term care of the patient with mCRPC
by: I N Zaborskiy, et al.
Published: (2014-12-01)

Navigating the mCRPC Landscape: Exploring Key Clinical Decision Points
by: Fred Saad, et al.
Published: (2015-05-01)

Abiraterone In Vitro Is Superior to Enzalutamide in Response to Ionizing Radiation
by: Timothy C. Wright, et al.
Published: (2021-07-01)

Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC
by: Ralph E. White, et al.
Published: (2023-06-01)

Observational study on time on treatment with abiraterone and enzalutamide.
by: Giuseppe Fallara, et al.
Published: (2020-01-01)

Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
by: Iván Henríquez, et al.
Published: (2021-09-01)

A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and Russia
by: Dingwei Ye, et al.
Published: (2017-04-01)

PROpel trial: Are PARP inhibitors ready to become the first-line treatment for mCRPC?
by: Abhay Singh Gaur
Published: (2022-01-01)

Bone pain palliation outcomes and possibility of Radium-223 re-treatment in mCRPC
by: Viviana Frantellizzi, et al.
Published: (2020-10-01)

A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study)
by: Pierangela Sepe, et al.
Published: (2024-01-01)

Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE
by: Daniele Santini, et al.
Published: (2021-02-01)

Abiraterone is associated with higher odds of cardiac complications compared to enzalutamide
by: E.B. Cone, et al.
Published: (2020-07-01)

Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
by: Giorgia Gurioli, et al.
Published: (2020-09-01)

Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
by: Melissa Gamat-Huber, et al.
Published: (2020-09-01)

Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model
by: Nourridine Siewe, et al.
Published: (2022-01-01)

Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model.
by: Nourridine Siewe, et al.
Published: (2022-01-01)

The Many Faces Of mCRPC- Assessing Patient Profiles and Tailoring Treatment in a Changing Landscape
by: Manfred Wirth, et al.
Published: (2014-05-01)

Association between the Immunophenotype of Peripheral Blood from mCRPC Patients and the Outcomes of Radium-223 Treatment
by: Elisabet Cantó, et al.
Published: (2023-06-01)

Potential prognostic value of miR-132 and miR-212 expression in mCRPC patients
by: Mariano Pontico, et al.
Published: (2021-10-01)

IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)
by: Holden T Maecker, et al.
Published: (2021-08-01)

Addition of Standard Enzalutamide Medication Shows Synergistic Effects on Response to [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in mCRPC Patients with Imminent Treatment Failure—Preliminary Evidence of Pilot Experience
by: Florian Rosar, et al.
Published: (2022-05-01)

Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review
by: Yash B. Shah, et al.
Published: (2022-08-01)